Here’s a bold statement: the future of lung cancer treatment might just be getting a game-changing update, and it’s all thanks to a promising new combination therapy. But here’s where it gets controversial—what if we could effectively treat a type of lung cancer that’s notoriously difficult to manage? Early results from a groundbreaking study suggest that the combination of STK-012, pembrolizumab (Keytruda), and chemotherapy could be a beacon of hope for patients with PD-L1–negative nonsquamous non–small cell lung cancer (NSCLC). This is the part most people miss: even in patients with tumors that resist traditional immunotherapy, this regimen is showing remarkable potential.
Presented at the 2025 SITC Annual Meeting, data from the phase 1a/1b STK-012-101 trial (NCT05098132) revealed that this combination not only demonstrated early efficacy but also maintained a manageable safety profile. And this is the part that’s sparking debate—could this approach redefine how we treat hard-to-manage lung cancers? Let’s dive into the details.
In the study, no dose-limiting toxicities were reported, and most treatment-related adverse effects (TRAEs) were mild to moderate, reversible, and did not lead to treatment discontinuation. Notably, only one grade 4 TRAE (neutropenia) was observed, with no grade 5 toxicities. Even more striking, there were no significant interleukin-2 (IL-2)–related adverse effects, a common concern with similar therapies.
At a median follow-up of 4 months, the regimen achieved an objective response rate (ORR) of 55% in all evaluable patients (n = 22), with a disease control rate (DCR) of 96%. For patients with a PD-L1 tumor proportion score (TPS) below 1% (n = 18), the ORR was 50%, and the DCR remained high at 94%. Here’s the kicker—responses deepened over time, even in patients with challenging mutations like STK11 and KEAP1, suggesting this therapy could offer lasting benefits.
Top Takeaways:
1. The combination achieved a 55% response rate and a 96% disease control rate in PD-L1–negative nonsquamous NSCLC patients.
2. Responses improved over time, even in patients with difficult-to-treat mutations, with most remaining on treatment.
3. The regimen demonstrated manageable, reversible toxicity and no significant IL-2–related adverse effects, paving the way for phase 2 trials.
Dr. Adam J. Schoenfeld of Memorial Sloan Kettering Cancer Center noted, ‘Early data from STK-012 plus standard-of-care chemotherapy are encouraging. If these results hold up in larger studies, they could transform treatment for these challenging cancers.’ But here’s the question: Is this the breakthrough we’ve been waiting for, or is it too early to celebrate?
The study design included two phases: phase 1a enrolled treatment-naive patients with stage IV nonsquamous NSCLC, regardless of PD-L1 expression, while phase 1b focused on patients with a PD-L1 TPS below 1%. STK-012 was administered subcutaneously, pembrolizumab intravenously, and chemotherapy (pemetrexed and carboplatin) as per standard protocols. The primary endpoint was safety, with ORR as a key secondary endpoint.
In terms of safety, the regimen was well-tolerated. At a median follow-up of 3.12 months, 25 patients were evaluable, with grade 1/2 TRAEs in 52% and grade 3/4 TRAEs in 28%. Common side effects included nausea, fatigue, rash, and injection site reactions, all of which were manageable. But here’s the real question—could this safety profile make it a preferred option over existing treatments?
Looking ahead, the phase 2 SYNERGY-101 trial is already underway, recruiting 105 treatment-naive patients with advanced nonsquamous NSCLC and a PD-L1 TPS below 1%. Patients will be randomized to receive STK-012 at different doses with chemotherapy or chemotherapy alone. The primary endpoint is ORR, and results could further solidify this therapy’s potential.
What do you think? Is this combination the next big thing in lung cancer treatment, or are we getting ahead of ourselves? Share your thoughts in the comments—let’s keep the conversation going!
